Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice

Mark Katzenellenbogen, Lina Mizrahi, Orit Pappo, Naama Klopstock, Devorah Olam, Hila Barash, Eytan Domany, Eithan Galun and Daniel Goldenberg
Mark Katzenellenbogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina Mizrahi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orit Pappo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naama Klopstock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devorah Olam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hila Barash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eytan Domany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eithan Galun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Goldenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0420 Published April 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Effect of chemopreventive agents on liver function in 3-month-old mice. A, liver to body weight (%). White, untreated Mdr2 heterozygotes; black, untreated Mdr2-KO; diagonal hatching, Mdr2-KO treated with tannic acid; gray, Mdr2-KO treated with selenomethionine (four males in each group). B, levels of liver enzymes and cholesterol in serum (units). Abbreviations: TA, tannic acid; SEM, selenomethionine; ALT, alanine aminotransferase; ALP/4, alkaline phosphatase level divided into 4 (to fit to the scale); AST, aspartate aminotransferase; CHOL, cholesterol.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effect of chemopreventive agents on the liver histology and PCNA expression in 3-mo-old mice. Top, H&E staining; middle and bottom, staining with anti-PCNA antibody. +/−, control Mdr2 heterozygous mice. Abbreviations: KO, Mdr2-KO mice; No, no treatment; TA, treatment with tannic acid; SEM, treatment with selenomethionine.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effect of chemopreventive agents on the incidence of liver tumors in 16-mo-old Mdr2-KO mice. A, incidence of tumors with linear size >1 cm. B, incidence of tumors with linear size between 0.5 and 1 cm. No, no treatment (13 males and 8 females); TA, treatment with tannic acid (8 males and 17 females); SEM, treatment with selenomethionine (8 males and 12 females). *, P < 0.05, statistically significant in comparison with untreated animals by Fisher's exact test.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Effect of chemopreventive agents on the expression levels of genes differentially expressed in Mdr2-KO mice. A, the reversion indices in a 10-point scale (see Materials and Methods) for untreated Mdr2-KO mutants (Mut) and heterozygotes (Het) and Mdr2-KO mutants treated with tannic acid (MutTA) or selenomethionine (MutSe). The indices are sorted in the order of average treatment effect. B, distance matrix of samples in the space of differentially expressed genes. The matrix was obtained by data reordering using the SPIN algorithm (see Materials and Methods). The distances are color-coded (the warmer the color, the bigger the distance).The sample order is identical in rows and columns (diagonal, distance between each sample and itself). C, distance matrix of samples in the space of significant pairs of genes (see Materials and Methods). The only difference with (B) is the usage of gene expression values relative for pairs of genes instead of individual values.

Tables

  • Figures
  • Table 1.

    Description of mice sacrificed at different stages of the experiment

    No treatment
    Tannic acid
    Selenomethionine
    3 mo16 mo3 mo16 mo3 mo16 mo
    Mdr2-KO4 males13 males4 males8 males3 males8 males
    8 females17 females12 females
    Mdr2+/−4 males3 males3 males3 males4 males8 males
    4 females6 females6 females
  • Table 2.

    Pathologic scores of liver tissues from 3-mo-old Mdr2-KO and Mdr2+/− control mice either untreated or treated with tannic acid or selenomethionine

    Treatment/genotypeDuctular proliferationPortal inflammationFibrosisMitotic activityCouncilman bodiesTotal score
    Untreated
        Mdr2+/−0 ± 00 ± 00 ± 00.5 ± 0.40.3 ± 0.50.8 ± 0.5
        Mdr2-KO3.0 ± 02.7 ± 0.62.3 ± 0.60.7 ± 0.52.0 ± 1.110.7 ± 1.5
    Tannic acid treated
        Mdr2+/−0 ± 00 ± 00 ± 01.0 ± 1.70 ± 01.0 ± 1.7
        Mdr2-KO3.0 ± 03.0 ± 03.0 ± 01.0 ± 1.70.7 ± 0.610.7 ± 2.1
    Selenomethionine treated
        Mdr2+/−0 ± 00 ± 00 ± 00 ± 00.7 ± 0.60.7 ± 0.6
        Mdr2-KO2.7 ± 0.62.7 ± 0.61.3 ± 0.60.3 ± 0.61.3 ± 0.68.3 ± 1.2
    • NOTE: Pathologic scores were calculated as described in van Nieuwerk et al. (49).

PreviousNext
Back to top
Molecular Cancer Therapeutics: 6 (4)
April 2007
Volume 6, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice
Mark Katzenellenbogen, Lina Mizrahi, Orit Pappo, Naama Klopstock, Devorah Olam, Hila Barash, Eytan Domany, Eithan Galun and Daniel Goldenberg
Mol Cancer Ther April 1 2007 (6) (4) 1283-1291; DOI: 10.1158/1535-7163.MCT-06-0420

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice
Mark Katzenellenbogen, Lina Mizrahi, Orit Pappo, Naama Klopstock, Devorah Olam, Hila Barash, Eytan Domany, Eithan Galun and Daniel Goldenberg
Mol Cancer Ther April 1 2007 (6) (4) 1283-1291; DOI: 10.1158/1535-7163.MCT-06-0420
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement